Skip to main content
SpringerLink
Log in

Impact of 2013 EMA regulatory action on diclofenac prescribing

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. in response to an elevated risk of acute cardiovascular events with systemic formulations of diclofenac

Reference

  • Morales DR, et al. Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands. Pharmacoepidemiology and Drug Safety : [10 pages], 3 Jan 2020. Available from: URL: http://doi.org/10.1002/pds.4955

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Impact of 2013 EMA regulatory action on diclofenac prescribing. Reactions Weekly 1787, 7 (2020). https://doi.org/10.1007/s40278-020-73645-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-73645-0

Search

Navigation